Skip to main content
Go to the home page of the European Commission (opens in new window)
English en
CORDIS - EU research results
CORDIS

THREE STOP CODONS TO GET OVER TO FLOURISH

Project description

Rewriting the premature full stop in our genes

For decades, biology textbooks have taught that the genetic code is fixed: three letters form a coding codon, and three codons signal 'stop' at the end of the coding region of each mRNA. When a stop signal appears in the coding region of mRNA as a result of a mutation, it leads to a truncated protein and disease. The ERC-funded 3Stops2Go project aims to challenge this. In single-celled protists such as Blastocrithidia nonstop, researchers have found that stop codons can be reinterpreted thanks to unusual transfer RNAs that read through them. By exploring this flexible decoding system, the project will engineer tRNAs and readthrough drugs capable of overriding faulty stop signals in human cells. The findings could pave a new therapeutic path for severe genetic diseases.

Objective

An accumulating body of evidence reveals that the Genetic Code, canonically interpreted in codons of three nucleotides, is not universal. In dogma challenging findings, we have observed in unicellular protists a remarkable malleability of genetic decoding that is mostly governed by tRNAs that interpret codons as having different meanings depending on their location in the genome. For example, coding sequences of our model protist Blastocrithidia nonstop are rich in stop codons and unique tRNA architectures are employed to readthrough them efficiently. Importantly, these internal stops very much resemble premature termination codons (PTC) in humans that lead to truncated proteins and are the cause of ~11% of human genetic disease. As such, these small RNA molecules with innate readthrough properties hold tremendous promise for the treatment of disease.
Our first objective is to explore and characterize the molecular mechanisms of alternative genetic decoding in protists where this phenomenon is most prominent. Armed with this knowledge, our second objective is to engineer tRNAs and tRNA-specific readthrough-inducing drugs (TRIDs) for programmable alterations of genetic decoding in heterologous systems. tRNAs and TRID will then be applied in cellular and animal models of severe monogenic paediatric diseases.
We have assembled a team that synergizes expertise across disciplines. JL is a leading protist biologist, LV specializes on translational control, ON in engineering stop codon readthrough drugs, and MO in clinical disease models. This intertwined collaboration of all four PIs will expedite the characterization of alternative decoding mechanisms and their ultimate application in cellular and in vivo models of human diseases. Successful completion of 3Stops2Go is only possible by close teamwork and aims to deliver a new class of tRNA molecules and readthrough pharmaceuticals that will be a paradigm shift in basic science with direct and broad therapeutic potential.

Fields of science (EuroSciVoc)

Keywords

Programme(s)

Topic(s)

Funding Scheme

HORIZON-ERC-SYG - HORIZON ERC Synergy Grants

See all projects funded under this funding scheme

Call for proposal

(opens in new window) ERC-2025-SyG

See all projects funded under this call

Host institution

MIKROBIOLOGICKY USTAV AV CR V.V.I
Net EU contribution
€ 2 599 960,00
Address
VIDENSKA 1083
142 00 PRAHA 4
Czechia
Region
Česko Praha Hlavní město Praha
Activity type
Research Organisations
Links
Total cost
€ 2 599 960,00

Beneficiaries (6)